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Exposure of insulin-sensitive tissues to free fatty acids
can impair glucose disposal through inhibition of car-
bohydrate oxidation and glucose transport. However,
certain fatty acids and their derivatives can also act as
endogenous ligands for peroxisome proliferator-acti-
vated receptor g (PPARg), a nuclear receptor that posi-
tively modulates insulin sensitivity. To clarify the ef-
fects of externally delivered fatty acids on glucose
uptake in an insulin-responsive cell type, we systemati-
cally examined the effects of a range of fatty acids on
glucose uptake in 3T3-L1 adipocytes. Of the fatty acids
examined, arachidonic acid (AA) had the greatest posi-
tive effects, significantly increasing basal and insulin-
stimulated glucose uptake by 1.8- and 2-fold, respec-
tively, with effects being maximal at 4 h at which time
membrane phospholipid content of AA was markedly
increased. The effects of AA were sensitive to the inhi-
bition of protein synthesis but were unrelated to
changes in membrane fluidity. AA had no effect on total
cellular levels of glucose transporters, but significantly
increased levels of GLUT1 and GLUT4 at the plasma
membrane. While the effects of AA were insensitive to
cyclooxygenase inhibition, the lipoxygenase inhibitor,
nordihydroguaiaretic acid, substantially blocked the AA
effect on basal glucose uptake. Furthermore, adenoviral
expression of a dominant-negative PPARg mutant atten-
uated the AA potentiation of basal glucose uptake. Thus,
AA potentiates basal and insulin-stimulated glucose up-
take in 3T3-L1 adipocytes by a cyclooxygenase-inde-
pendent mechanism that increases the levels of both
GLUT1 and GLUT4 at the plasma membrane. These ef-
fects are at least partly dependent on de novo protein
synthesis, an intact lipoxygenase pathway and the acti-
vation of PPARg with these pathways having a greater
role in the absence than in the presence of insulin.
A full understanding of the control of glucose homeostasis
and its dysregulation in diabetes mellitus will require a better
comprehension of the integration of carbohydrate and lipid
metabolism (1). Free fatty acids are considered to play a pivotal
role in the pathogenesis of diabetes and may be involved in the
early events leading to insulin resistance in man (2). The clas-
sic studies of Randle and colleagues (3) demonstrated that
oxidation of fatty acids could inhibit glucose oxidation through
the effects of acetyl-CoA on pyruvate dehydrogenase activity.
More recently it has been shown that increased delivery of free
fatty acids in vivo can impair insulin-mediated glucose disposal
through inhibition of glucose uptake (4–7). Furthermore, sev-
eral long chain fatty acids, both saturated and unsaturated,
have been demonstrated to decrease mRNA levels of the insu-
lin-responsive glucose transporter GLUT4 in vitro (8).
Insulin sensitivity in whole animals can also be influenced by
the manipulation of the dietary fatty acid profile. A diet high in
saturated, monounsaturated (n-9) or polyunsaturated (n-6)
fatty acids (PUFA)1 leads to insulin resistance in rodents (9,
10). Substituting a small percentage of fatty acids in the n-6
PUFA diet with n-3 PUFA normalizes insulin action (9, 10).
Similar dietary intervention studies in humans have been in-
conclusive (11). However, in both humans and rodents, PUFA
(particularly n-3) levels in skeletal muscle membrane phospho-
lipids are positively correlated with insulin sensitivity (10, 12,
13).
In addition to their roles as metabolic fuel, certain fatty acids
can act as precursors for signaling molecules which may influ-
ence insulin action and glucose metabolism. Interest in these
activities has been greatly enhanced by the recent recognition
of the importance of the nuclear hormone receptor PPARg in
the control of insulin sensitivity (14, 15). Thus, pharmacologi-
cal agonists for PPARg can enhance glucose disposal both in
vitro (16–18) and in vivo (19) and loss of function mutations in
human PPARg result in extreme insulin resistance and diabe-
tes mellitus (20). While the true endogenous ligand(s) for
PPARg have not been established with certainty, the receptor
can be activated in vitro by a variety of lipophilic ligands
including certain polyunsaturated fatty acids (21–25) and their
metabolites (21, 24, 26–29).
Grunfeld et al. (30) originally reported that exposure of
3T3-L1 adipocytes to certain unsaturated fatty acids during
differentiation could enhance basal glucose uptake. These
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workers suggested that relatively nonspecific effects on mem-
brane fluidity might underlie these effects. More recently, a
similar effect on basal glucose uptake has been observed in
fully differentiated 3T3-L1 adipocytes supplemented with the
n-6 PUFA, arachidonic acid (AA) (31, 32). In light of recent
advances in the understanding of the possible roles of lipid
mediators in the control of glucose homeostasis we have re-
examined the effects of a range of fatty acids on glucose uptake
in 3T3-L1 adipocytes. Having established that AA had the most
marked effects on enhancement of glucose disposal we have
attempted to dissect the molecular mechanisms underlying
these effects.
EXPERIMENTAL PROCEDURES
Materials—2-Deoxy-D-[2,6-3H]glucose, [1-14C]AA, and the enhanced
chemiluminescence (ECL) kit were purchased from Amersham Phar-
macia Biotech. Analytical grade solvents were obtained from BDH
Biochemicals (Dorset, United Kingdom). Rabbit anti-GLUT4 antibody
was a gift from Prof. G. Gould (University of Glasgow), rabbit anti-
GLUT1 was a gift from Prof. S. Baldwin (University of Leeds), and
rabbit anti-PPARg was a gift from Dr. M. Lazar (University of Penn-
sylvania School of Medicine). The PGE2 monoclonal enzyme immuno-
assay kit was purchased from Cayman Chemical. Ibuprofen, 6-me-
thoxy-2-napthylacetic acid (6-MNA), and piroxicam were purchased
from Biomol Research Laboratories. The RNeasy total RNA kit was
from Qiagen. Rosiglitazone was provided by Dr. S. Smith (SmithKline
Beecham Pharmaceuticals). Reverse transcription reagents were ob-
tained from Promega, UK, and TaqMan reagents were from PE Biosys-
tems. All other reagents were from Sigma.
Tissue Culture—3T3-L1 fibroblasts (ATCC) were maintained at no
higher than 70% confluency in DMEM containing 10% newborn calf
serum, 25 mM glucose, 2 mM glutamine, and antibiotics (DMEM/NBCS).
For differentiation they were grown 2 days post-confluence in DMEM/
NBCS and then for 2 days in medium containing fetal bovine serum
instead of newborn calf serum (DMEM/FBS) supplemented with 0.83
mM insulin, 0.25 mM dexamethasone, and 0.5 mM isobutylmethylxan-
thine. The medium was then changed to DMEM/FBS supplemented
only with 0.83 mM insulin for 2 days and then to DMEM/FBS alone for
a further 3–5 days. Differentiated cells were only used when at least
95% of the cells showed an adipocyte phenotype by accumulation of lipid
droplets.
Fatty Acid Solutions—Fatty acid-supplemented media were pre-
pared as described previously (30). In short, a 0.2 M stock solution of the
fatty acid in ethanol was diluted 1:25 into 20% fatty acid-free bovine
serum albumin in Dulbecco’s phosphate-buffered saline (PBS) at 60 °C
with shaking. This solution was diluted 1:10 into serum-free DMEM
(containing 25 mM glucose and 2 mM glutamine) for studies with up to
4-h incubation times, or into DMEM/FBS for studies with .4-h incu-
bation times. This gives a final concentration of 8 3 1024 M fatty acid
and 0.4% ethanol.
Glucose Uptake—Adipocytes (at day 9 after initiation of differentia-
tion) in 6- (or 24-) well plates were incubated for 4 h in fatty acid-
supplemented DMEM. In the time course experiment, incubations of 48
and 24 h were commenced on days 7 and 8 of differentiation, respec-
tively, and on day 9 cells were serum-starved in DMEM (containing 25
mM glucose and 2 mM glutamine) for 2 h prior to the assay. For the 1-h
time point, cells were starved for 1 h prior to incubation in the AA
medium. Glucose uptake assays were performed as described previ-
ously (33).
Western Blotting—Treated cells (adipocytes/pre-adipocytes) were sol-
ubilized by scraping and passing 10 times through a 25-gauge needle in
lysis buffer (50 mM Hepes, 150 mM NaCl, 1 mM EDTA, 30 mM NaF, 1%
Triton X-100, 1 mM Na3VO4, 10 mM Na2P2O7, 2.5 mM benzamidine, 1
mg/ml antipain, 1 mg/ml leupeptin, 1 mg/ml pepstatin A). The lysate was
clarified by centrifugation at 13,500 3 g for 10 min at 4 °C. Crude cell
extracts were resolved by SDS-PAGE before electroblotting to polyvi-
nylidene difluoride membranes (Millipore). Membranes were blocked in
1% bovine serum albumin and specific proteins were detected by incu-
bation with appropriate primary and secondary (horseradish peroxi-
dase-conjugated) antibodies in TBST (150 mM NaCl, 50 mM Tris, 0.1%
Tween 20). Proteins were visualized using an ECL kit.
Plasma Membrane Lawn Assay—3T3-L1 adipocytes (day 9), grown
on collagen-coated glass coverslips, were treated for 4 h with AA me-
dium. Cells were incubated 6 10 nM insulin for 30 min and a modified
version of the plasma membrane lawn assay (33) was performed. Cells
were washed twice in ice-cold buffer A (50 mM Hepes, 10 mM NaCl, pH
7.2), twice in ice-cold buffer B (20 mM Hepes, 10 mM KCl, 2 mM CaCl2,
1 mM MgCl2, pH 7.2), and sonicated using a probe sonicator (Kontes,
Vineland, NJ) to generate a lawn of plasma membrane fragments
attached to the coverslip. The membranes were washed twice again in
ice-cold buffer B and fixed to the coverslips for 15 min using freshly
prepared 3% paraformaldehyde. Membranes were then serially
washed: 3 times in PBS, 3 times in 50 mM NH4Cl in PBS over 10 min,
3 times in PBS, 3 times in PBS-gelatin (PBS containing 0.2% gelatin
and 1 ml/ml goat serum) over 5 min, and finally 3 times in PBS.
Membranes were incubated in either anti-GLUT4 or anti-GLUT1 anti-
body (1:100 dilution in PBS-gelatin) for 1 h at room temperature. After
washing 3 times in PBS-gelatin and 3 times in PBS, the coverslips were
incubated with the secondary antibody, fluorescein isothiocyanate-con-
jugated donkey anti-rabbit IgG for 1 h at room temperature, washed 3
times in PBS-gelatin, and 3 times in PBS and mounted on glass slides.
Coverslips were viewed using a 360 objective lens on a Nikon Optiphot-
2/Bio-Rad MRC-1000 microscope operated in laser scanning confocal
mode. Samples were illuminated at 488 nm, and images were collected
at 510 nm. Duplicate coverslips were prepared at each experimental
condition and eight random images of plasma membrane lawn were
collected from each. The images were quantified using Bio-Rad MRC-
1000 confocal microscope operating software (CoMOS, version 6.05.8),
on an AST premmia SE P/60 personal computer.
[1-14C]Arachidonic Acid Uptake—0.2 M AA, containing a trace of
[1-14C]AA, was diluted into 20% bovine serum albumin and serum-free
DMEM to a final concentration of 8 3 1024 M as described above.
3T3-L1 adipocytes (day 9) in six-well plates were supplemented with 2
ml of medium containing 0.05 mCi of [1-14C]AA per well for 2, 4, 6, 8, and
10 h. At these time points, media was removed and cells were washed
twice with PBS. Cells were solubilized in 1 ml of 0.1 M NaOH per well
and quenched using 50 ml of concentrated HCl. Radioactivity in media
and cell samples was determined by liquid scintillation counting.
Membrane Preparation, Phospholipid Extraction, and Fatty Acid
Analysis—3T3-L1 adipocytes (day 9) in 3 3 T175 tissue culture flasks
were treated with 8 3 1024 M AA for 4 h. Cells were washed twice with
PBS and solubilized by scraping in 4 ml of PBS/flask and passing 10
times through a 25-gauge needle. Cell lysates were spun at 10,000 3 g
for 10 min at 4 °C to remove nuclei and mitochondria and at 100,000 3
g for 1 h at 4 °C to pellet membranes. The supernatant, including the
floating triglyceride layer, was removed and the pellet resuspended in
1 ml of PBS by passing 10 times through a 27-gauge needle. Total lipids
were extracted and phospholipids separated and transmethylated as
described previously (34). The resulting fatty acid methyl esters were
separated and measured on a Unicam 610 gas chromatograph with
flame ionization detection and a 30 m 3 0.53-mm Supelco SP2380
megabore column. Helium was used as the carrier gas at a flow rate of
19.4 ml/min. A temperature gradient program was used with an initial
temperature of 70 °C increasing at 1 °C/min to 180 °C, then 5 °C/min to
200 °C and remaining at 200 °C for a further 6 min. Identification of
fatty acid methyl esters was made by comparison with retention times
of standard mixtures.
Membrane Fluidity Assay—3T3-L1 adipocytes (day 9) in 2 3 6-well
plates were treated with 8 3 1024 M AA for 4 h. Cells were washed and
solubilized in PBS and membranes were prepared as described above.
Fluidity of the membranes was assessed by measurement of steady
state fluorescence polarization of 1,6-diphenyl-1,3,5-hexatriene incor-
porated into the hydrophobic core of the membrane bilayer. A modified
version of the previously described assay (35) was performed. Briefly, a
stock solution of 250 mM 1,6-diphenyl-1,3,5-hexatriene in tetrahydrofu-
ran was prepared. 0.9 mg of membrane in 3 ml of PBS was incubated for
30 min in the dark with 0.25 mM 1,6-diphenyl-1,3,5-hexatriene at 37 °C.
Fluorescence anisotropy measurements were performed in a
PerkinElmer Life Sciences (LS-5B) luminescence spectrometer at 37 °C,
with excitation and emission wavelengths of 360 and 430 nm, respec-
tively, and slit widths of 10 nm. Intensities were corrected for intrinsic
membrane fluorescence by using the tetrahydrofuran vehicle. Fluores-
cence anisotropy is inversely proportional to membrane fluidity.
Inhibitor Studies—Fresh stock solutions of inhibitors were prepared
in absolute ethanol (ibuprofen, nordihydroguaiaretic acid, and cyclohex-
imide) or dimethyl sulfoxide (piroxicam and 6-MNA). 3T3-L1 adipocytes
(day 9) in 6-well plates were given 1.8 ml of serum-free DMEM and 20
ml of inhibitor solution for 30 min. 0.2 M AA in ethanol was diluted 1:25
into 20% fatty acid-free bovine serum albumin in PBS as before and 200
ml of this solution was added per well for 4 h. This gives a final 1:100
dilution of the original inhibitor stock solution. The glucose uptake
assay was performed as above.
Enzyme Immunoassay for PGE2—Cells were treated 6AA/inhibitor
for 4 h. 1-ml aliquots of medium were taken immediately prior to the
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glucose uptake assay and analyzed for PGE2 content using an enzyme
immunoassay kit for PGE2 (Cayman Chemical) based on the enzyme-
linked immunosorbent assay method.
Adenovirus Expression—Recombinant adenoviruses were generated
as described previously (36), expressing GFP (Ad-GFP) or GFP and
full-length L468A/E471A human PPARg1 (Adgm). 3T3-L1 preadipocyte
(2 days post-confluence) or day 7 adipocyte cultures in 24-well plates
were infected with recombinant virus by addition of 1 3 109 plaque-
forming units/well. 12 h later medium containing free virus was re-
moved and appropriate experimental medium was added. Comparable
viral infection efficiency was verified by microscopy using a Zeiss axio-
vert 135 inverted fluorescence microscope. Only cells with .70% infec-
tivity were used in experiments.
RNA Extraction/Quantitative Reverse Transcriptase-PCR—Virally
infected pre-adipocytes/day 2 adipocytes were scraped and total RNA
was extracted using the RNeasy mini kit from Qiagen. Adipocyte P2
(aP2) gene expression was quantified using real time quantitative re-
verse transcriptase-PCR. Briefly, cDNA was prepared from 100 ng of
RNA using 200 units of Moloney murine leukemia virus reverse tran-
scriptase (Promega). Real time quantitative PCR was performed using
an ABI-PRISM 7700 Sequence Detection System instrument and soft-
ware (PE Applied Biosystems, Inc., Foster City, CA) as described (37).
The primers and probes for aP2 were: forward, CACCGCAGACGACA-
GGAAG; reverse, GCACCTGCACCAGGG; probe, TGAAGAGCATCAA-
ACCCTAGATGGCGG (all 59-39). Results were normalized to the endog-
enous control, glyceraldehyde-3-phosphate dehydrogenase.
Statistical Analysis—Data are presented as mean 6 S.E. Statistical
significance of treatments was determined using the paired Student’s t
test (*, p , 0.05; **, p , 0.01; ***, p , 0.001).
RESULTS
Effect of Fatty Acids on Glucose Uptake in 3T3-L1 Adipo-
cytes—Fully differentiated 3T3-L1 adipocytes were incubated
with 8 3 1024 M free fatty acids for 4 h and basal and insulin-
stimulated glucose uptake was compared with cells incubated
in vehicle alone. Ten different fatty acids were studied, includ-
ing several members of the n-3 and n-6 series.2 Basal glucose
uptake was significantly increased with 16:1(n-7), 20:3(n-6),
20:4(n-6), 18:3(n-3), and 22:6(n-3) with all others showing a
nonsignificant trend in the same direction (Fig. 1A). All fatty
acids, except 16:0, significantly increased insulin-stimulated
glucose uptake. The largest effect on glucose uptake was ob-
served with 20:4(n-6) (AA). This increased basal glucose uptake
by 1.8-fold and insulin-stimulated glucose uptake 2-fold. To
establish the time course of these effects, cells were incubated
with AA for 1, 2, 4, 24, and 48 h. Significant enhancement of
glucose uptake, both basal and insulin stimulated, was seen
from 4 h onward, at which time point maximum effects were
seen (Fig. 1B). In repeat experiments, occasional cellular tox-
icity was noted at 24- and 48-h exposures. Concentrations of
AA lower than 5 3 1024 M had no discernible effect (data not
shown). All further experiments were undertaken using 8 3
1024 M AA at the 4-h time point.
Effect of Arachidonic Acid on the Expression and Cellular
Localization of Glucose Transporters—Arachidonic acid had no
effect on total cellular levels of GLUT1 and GLUT4 as assessed
by Western blotting (Fig. 2A). To examine whether AA might
have an effect on levels of GLUT1 or GLUT4 at the plasma
membrane the plasma membrane lawn assay was used. Insulin
treatment of 3T3-L1 cells produced an ;2-fold increase in
GLUT1 and a 5-fold increase in GLUT4 plasma membrane
expression, results which are consistent with previous pub-
lished studies (33). AA increased levels of GLUT1 at the plasma
membrane in the absence and presence of insulin by 2- (p ,
0.05) and 1.3-fold (p , 0.001), respectively, and increased levels
of GLUT4 at the plasma membrane in the absence and pres-
ence of insulin by 1.5-fold (p , 0.01) and 1.4-fold (p , 0.05),
respectively (Fig. 2B).
Effect of Arachidonic Acid on Membrane Phospholipid Com-
position and Fluidity—The rapidity of the effects of AA on
glucose uptake raised the question of whether the uptake of AA
into the cell and its incorporation into membrane phospholipid
could be accomplished significantly within 4 h. 3T3-L1 adipo-
cytes were incubated with [1-14C]AA. Within 4 h, the cells had
taken up approximately half of the labeled AA (Fig. 3A). 4 h
incubation in 8 3 1024 M AA also had a highly significant effect
on the fatty acid composition of cellular membranes with a
4.5-fold increase in the AA content of membrane phospholipid
(p , 0.001) (Fig. 3B). The positive effects of AA on glucose
uptake did not appear to be mediated by nonspecific effects on
membrane fluidity which was unchanged after 4 h of incuba-
tion with AA (Fig. 3C).
Effects of the Inhibition of Protein Synthesis—The protein
2 The following fatty acid nomenclature was used: 16:0, palmitic acid;
16:1(n-7), palmitoleic acid; 18:2(n-6), linoleic acid; 18:3(n-6), g-linolenic
acid; 20:3(n-6), dihomo-g-linolenic acid (DGLA); 20:4(n-6), arachidonic
acid; 22:4(n-6), adrenic acid; 18:3(n-3), a-linolenic acid; 20:5(n-3), EPA;
and 22:6(n-3), DHA.
FIG. 1. Glucose uptake. A, effect of fatty acids. Day 9 adipocytes in
six-well plates were supplemented with 8 3 1024 M fatty acid in serum-
free DMEM for 4 h and stimulated for 30 min 6 10 nM insulin (open
columns, unstimulated; filled columns, stimulated). 2-Deoxyglucose up-
take was measured over 5 min as described under “Experimental Pro-
cedures.” Data are mean uptakes 6 S.E. from four or more independent
experiments performed in triplicate, normalized to vehicle insulin-stim-
ulated uptake (mean insulin responses, 21,630 dpm/well). B, time
course of AA supplementation. Days 7–9 adipocytes in six-well plates
were supplemented with 8 3 1024 M AA in serum-free DMEM (1, 2, and
4 h) or in DMEM/FBS followed by 2 h in serum-free DMEM (24 and
48 h) as described under “Experimental Procedures.” 2-Deoxyglucose
(DOG) uptake was measured over 5 min following stimulation 6 10 nM
insulin for 30 min. Data are mean uptakes 6 S.E. from four or more
independent experiments performed in triplicate, normalized to vehicle
insulin-stimulated uptake at each time point (mean insulin-responses,
17,000 dpm/well). Open columns, vehicle; filled columns, AA.
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synthesis inhibitor, cycloheximide, has previously been shown
to influence glucose uptake in 3T3-L1 adipocytes (38, 39) and it
was therefore important to choose a concentration which had
no effect on glucose uptake in the absence of AA. While 2.5 mM
cycloheximide had no effect on glucose uptake in control cells
(Fig. 4A), it completely inhibited the AA potentiation of basal
glucose uptake (p , 0.001) and partially inhibited the potenti-
ation of insulin-stimulated glucose uptake (p , 0.05) (Fig. 4B).
Thus, despite the fact that the effects of AA on glucose uptake
are rapid (4 h), these appear to be highly dependent on de novo
protein synthesis.
Effect of Inhibitors of Cyclooxygenase and Lipoxygenase on
the Arachidonic Acid Potentiation of Glucose Uptake—Arachi-
donic acid is rapidly converted to a number of eicosanoids. To
identify involvement of either cyclooxygenase (COX) or lipoxy-
genase (LOX) in the AA potentiation of glucose uptake, inhib-
itors of the two enzyme systems were used. Cyclooxygenase, or
prostaglandin H synthase, exists as two isozymes, COX1,
which is constitutively expressed, and COX2, which is induci-
ble (40). Ibuprofen inhibits both isozymes nonselectively with
an IC50 of 10 mM (41). Piroxicam and 6-MNA selectively inhibit
COX1 and COX2 with IC50 values of 18 and 15–55 mM, respec-
tively (42, 41). None of these COX inhibitors significantly in-
hibited either the AA potentiation of basal or insulin-stimu-
lated glucose uptake (Fig. 5A). To confirm that the COX
enzyme activity had indeed been inhibited in these experi-
ments, samples of media were taken prior to the studies of
glucose uptake and tested for the presence of prostaglandin E2,
a major metabolite of AA in the adipocyte (43). All three com-
pounds significantly inhibited the production of PGE2 from the
AA-supplemented cells (Fig. 5B).
Nordihydroguaiaretic acid (NDGA) is a selective inhibitor of
the lipoxygenases (IC50 5 0.2 mM for 5-LOX and 30 mM for 12-
and 15-LOX (44)). NDGA significantly inhibited the AA poten-
tiation of basal glucose uptake at both 30 mM (p , 0.05) and 60
mM (p , 0.01) and showed a similar trend to inhibit the poten-
tiation of insulin-stimulated uptake (p 5 0.08) (Fig. 5A).
Effect of Dominant-negative PPARg on the Arachidonic Acid
Potentiation of Glucose Uptake—The L468A/E471A human
PPARg1 mutant is a powerful dominant-negative inhibitor of
PPARg action (36). A recombinant adenovirus (Adgm) which
coexpresses this mutant PPARg receptor and green fluorescent
protein (GFP) has previously been demonstrated to markedly
inhibit thiazolidinedione-induced differentiation of human pre-
adipocytes (36). We first established that this virus could infect
both 3T3-L1 pre-adipocytes and differentiated 3T3-L1 adipo-
cytes with high efficiency, resulting in an increase in levels of
PPARg1 expression (Fig. 6A and Fig. 7, A and B). Adenoviral
infection with a control virus expressing only GFP (Ad-GFP)
had no effect on endogenous PPARg levels (Figs. 6A and 7B).
Expression of the dominant-negative PPARg in 3T3-L1 pre-
adipocytes significantly inhibited the induction of the differen-
tiation marker aP2 by rosiglitazone (p , 0.05) (Fig. 6B) and
also inhibited adipocyte differentiation in response to a stand-
ard differentiation mixture (p , 0.05) (Fig. 6C). No such effects
were seen with Ad-GFP (data not shown). Thus, these studies
confirmed that the human PPARg mutant receptor could in-
hibit the function of endogenous PPARg activity in a murine
pre-adipocyte line.
To investigate the effect of the PPARg mutant on the AA
potentiation of glucose uptake, 3T3-L1 adipocytes were in-
fected on day 7 of differentiation and the glucose uptake studies
were undertaken 2 days later. Transduction efficiencies were
ascertained by fluorescence microscopy (Fig. 7A) and plates
with ,70% infectivity were discarded. The high-level expres-
sion of mutant PPARg1 in Adgm-infected adipocytes was con-
firmed by Western blotting (Fig. 7B). In these cells Adgm sig-
nificantly inhibited the AA potentiation of basal, but not
insulin-stimulated, glucose uptake compared with cells in-
fected with the control virus (p , 0.01) (Fig. 7D). It is also
noteworthy that there was a trend for Adgm to reduce basal and
insulin-stimulated glucose uptake in the absence of AA
(Fig. 7C).
DISCUSSION
A role for fatty acids in the modulation of insulin sensitivity
in vivo and in vitro is well established (11), although the precise
nature of the mechanisms underlying these effects is unknown.
The recently established fact that certain fatty acids and their
metabolites can act as endogenous ligands for the nuclear
hormone receptor PPARg provides a potential mechanism (15).
With this in mind, we investigated the effect of a range of fatty
acids on glucose uptake in 3T3-L1 adipocytes. Having estab-
lished that AA had the most marked effect on the enhancement
of glucose uptake, we have attempted to dissect the molecular
FIG. 2. Effect of arachidonic acid on glucose transporters. Day
9 adipocytes were supplemented with 8 3 1024 M AA in serum-free
DMEM for 4 h. A, Western blotting. Cells were lysed as described under
“Experimental Procedures.” 40 mg of total protein was resolved by
SDS-PAGE and immunoblotted with anti-GLUT1 or GLUT4 antibody.
A representative gel is shown for each data set. Numerical data are
percentage mean 6 S.E. obtained by quantitation of gels from four
independent experiments, normalized to transporter levels in vehicle-
supplemented cells. Open columns, vehicle; filled columns, AA. B,
plasma membrane lawn assay. Cells were stimulated 6 10 nM insulin
for 30 min before preparation of plasma membrane lawns and assay of
glucose transporter translocation. Representative images from a typical
experiment are shown. Data from each experiment, utilizing 16 fields
for each condition, were quantified as described under “Experimental
Procedures” and overall results are shown as mean 6 S.E. from five
independent experiments. Open columns, unstimulated; filled columns,
10 nM insulin.
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events underlying this effect. Our studies have found that 4 h
of exposure to AA potentiates basal and insulin-stimulated
glucose uptake by increasing levels of GLUT1 and GLUT4 at
the plasma membrane. The potentiation of glucose uptake is
independent of cyclooxygenase but at least partly dependent on
an intact lipoxygenase pathway, de novo protein synthesis, and
PPARg activation. Our results also suggest that the molecular
mechanisms whereby AA potentiates basal versus insulin-stim-
ulated glucose uptake may differ slightly.
The systematic study of the effects of various fatty acids on
glucose uptake in adipocytes was first reported by Grunfeld et
al. (30). These workers showed that incubation of 3T3-L1 cells,
during the process of differentiation, with a range of saturated
and monounsaturated fatty acids increased basal glucose up-
take. Saturated fatty acids decreased insulin-stimulated up-
take, whereas monounsaturated fatty acids had no effect. Our
studies investigated the effect of 10 mainly polyunsaturated,
fatty acids on glucose uptake in fully differentiated 3T3-L1
adipocytes. Differentiated cells were used to eliminate con-
founding effects of fatty acids on the adipogenic process itself.
In agreement with Grunfeld et al. (30) there appeared to be a
relatively nonspecific effect of all fatty acids to increase basal
glucose uptake. However, all fatty acids studied, except the
saturated palmitic acid (16:0), increased insulin-stimulated
glucose uptake and this effect did not appear to be specific to
fatty acid series. The most marked effects on glucose uptake
were observed with AA, which increased basal and insulin-
stimulated glucose uptake at all time points studied. Two pre-
vious studies have shown a similar effect of AA on basal glucose
uptake in 3T3-L1 adipocytes. Fong et al. (32) observed an
increased basal glucose uptake with 0.2 mM AA at all time
points from 1 to 8 h (32). Similarly, Tebbey et al. (31) reported
such an effect with 50 mM AA following 24 and 72 h incubation.
Neither study, however, observed a significant effect of AA on
insulin-stimulated glucose uptake. Consistent with the obser-
vations of Fong et al. (32) who demonstrated that the potenti-
ating effects of 8 h exposure to AA on glucose uptake were
partially inhibited by cycloheximide, we found that the effects
of 4 h of AA were also sensitive to the inhibition of protein
synthesis suggesting the involvement of a rapidly synthesized
protein intermediate in the mediation of this response.
Having established the effect of AA on glucose uptake, we
FIG. 3. Effect of arachidonic acid on membrane phospholipid composition and fluidity. A, [1-14C]AA uptake. Day 9 adipocytes in
six-well plates were supplemented with 8 3 1024 M AA, including a trace of [1-14C]AA, in serum-free DMEM for 2, 4, 6, 8, and 10 h. Radioactivity
in media and cell lysates was measured. Data are mean dpm/well 6 S.E. from six wells in one representative experiment. Circles, medium;
triangles, cell lysate. B, membrane phospholipid fatty acid composition. Day 9 adipocytes in 3 3 T175 flasks were supplemented with 8 3 1024 M
AA in serum-free DMEM for 4 h. Membranes were prepared, phospholipids extracted, and their fatty acid composition analyzed as described under
“Experimental Procedures.” Data are mean percentage fatty acid composition of membrane phospholipids 6 S.E. from four independent
experiments. C, membrane fluidity. Day 9 adipocytes in six-well plates were supplemented with 8 3 1024 M AA in serum-free DMEM for 4 h.
Membranes were prepared and the fluidity assay performed as described under “Experimental Procedures.” Data are mean fluorescence anisotropy
“r” 6 S.E. from eight independent experiments performed in duplicate.
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examined whether this was mediated through increased ex-
pression or altered cellular location of glucose transporters.
Previous studies have demonstrated a decrease in total cellular
and plasma membrane GLUT4 in 3T3-L1 adipocytes supple-
mented with AA for 24 and 48 h (31, 8). Conversely, 3T3-L1
adipocytes supplemented with AA for 8 and 48 h exhibited
increased total cellular and plasma membrane levels of GLUT1
(32, 31). This effect was not, however, observed with 2 h AA
incubation (32). In our experiments, 4 h AA incubation had no
effect on total cellular levels of GLUT1 or GLUT4. However, a
highly significant increase in the plasma membrane levels of
both transporters, in the absence and presence of insulin was
observed. Thus AA appears to enhance either the translocation
of both major adipocyte glucose transporters to the plasma
membrane or reduce their rate of internalization.
It has been suggested that fatty acids may have nonspecific
effects on cellular membranes which could secondarily alter the
intrinsic activity of transmembrane glucose transporters (12,
30). In particular, alterations in the fatty acid composition of
membrane phospholipids can affect membrane fluidity (45). It
was unclear, however, whether as short an exposure as 4 h
would be sufficient to lead to such changes in plasma mem-
brane composition. We observed that, within 4 h, at least half
of the available AA had entered the cells and that there was a
highly significant increase in the AA content of membrane
phospholipids. However, this did not have any discernible ef-
fect on membrane fluidity. Therefore, although we have not
excluded an effect of AA on the intrinsic activity of membrane
glucose transporters any such effect is unlikely to be mediated
by changes in membrane fluidity.
Arachidonic acid is capable of being metabolized by both the
cyclooxygenase and the lipoxygenase enzyme systems. The re-
sulting metabolites have been implicated in the control of a
wide range of physiological and pathological processes. Inhibi-
tors of the individual enzyme systems were employed to exam-
ine which, if either, of these systems was involved in the gen-
eration of an AA metabolite that might mediate the effects on
glucose uptake. Cyclooxygenase, or prostaglandin H synthase,
catalyzes the conversion of AA to the prostanoids and the
thromboxanes. The enzyme exists as two isozymes, COX1,
which is constitutively expressed, and COX2, which is induci-
ble (40). We inhibited the COX enzyme activity in 3T3-L1
adipocytes for 30 min prior to addition of AA using ibuprofen
(nonselective), piroxicam (COX1), or 6-MNA (COX2). None of
these compounds inhibited the AA potentiation of either basal
or insulin-stimulated glucose uptake in our system, despite the
FIG. 4. Effect of cycloheximide on the arachidonic acid poten-
tiation of glucose uptake. Day 9 adipocytes were supplemented with
2.5 mM cycloheximide for 30 min and with 8 3 1024 M AA for a further
4 h as described under “Experimental Procedures.” Cells were stimu-
lated for 30 min 6 10 nM insulin and 2-deoxyglucose uptake was
measured over 5 min. A, data are mean 2-deoxyglucose (DOG) uptake 6
S.E. from seven independent experiments performed in triplicate, nor-
malized to nil cycloheximide (CHX), vehicle insulin-stimulated uptake
(mean insulin responses 19,800 dpm/well). Open columns, vehicle; filled
columns, AA. B, data from A is expressed as mean percentage difference
in glucose uptake (AA, cf. fatty acid vehicle) 6 S.E.
FIG. 5. Effect of metabolic inhibitors on the arachidonic acid
potentiation of glucose uptake. A, glucose uptake. Day 9 adipocytes
were supplemented with the indicated concentrations of inhibitors for
30 min and with 8 3 1024 M AA for a further 4 h as described under
“Experimental Procedures.” Cells were stimulated for 30 min 6 10 nM
insulin and 2-deoxyglucose uptake was measured over 5 min. Data are
mean percentage difference in 2-deoxyglucose uptake (AA, cf. fatty acid
vehicle) 6 S.E. from four or more independent experiments performed
in triplicate, normalized to inhibitor control (mean control values, ba-
sal, 57%; insulin, 128%). B, PGE2 enzyme immunoassay. Aliquots of
medium were removed immediately prior to the glucose uptake assay
and tested for the presence of PGE2. Data are mean picomole of PGE2/
ml 6 S.E. for AA-treated cells 6 inhibitor from four independent ex-
periments performed in triplicate. Fatty acid vehicle-treated cells gave
values below the level of detection of the EIA kit (4.25 pmol/ml).
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demonstration that the COX enzyme activity had indeed been
inhibited. These results contrast with those of Fong et al. (46)
who reported that indomethacin (a nonselective COX inhibitor)
inhibited the 8-h AA potentiation of basal glucose uptake. The
reasons for this discrepancy are unclear but may be explained
by the differing experimental conditions of the two studies,
FIG. 7. Transduction of 3T3-L1 adipocytes with dominant-negative PPARg. Day 7 adipocytes in 24-well plates were infected for 12 h with
1 3 109 pfu/well Ad-GFP or Adgm. Medium was changed to DMEM/FBS for 48 h. A, microscopy. Infection efficiency was estimated using
fluorescence microscopy. Representative images at 3320 magnification from a typical experiment are shown. B, Western blotting. Infected
adipocytes were scraped and lysed as described under “Experimental Procedures.” 10 mg of total protein was resolved by SDS-PAGE and
immunoblotted with anti-PPARg antibody. C and D, glucose uptake. Infected adipocytes were supplemented with 8 3 1024 M AA IN SERUM-FREE
DMEM FOR 4 H AND STIMULATED FOR 30 MIN 6 10 NM insulin. 2-Deoxyglucose uptake was measured over 5 min. C, data are mean 2-deoxyglucose
uptake 6 S.E. from four independent experiments performed in triplicate, normalized to Ad-GFP, vehicle insulin-stimulated uptake (mean insulin
responses 11,310 dpm/well). Open columns, vehicle; filled columns, AA. D, data from C is expressed as mean percentage difference in glucose
uptake (AA, cf. fatty acid vehicle) 6 S.E.
FIG. 6. Transduction of 3T3-L1 pre-adipocytes with dominant-negative PPARg. Confluent pre-adipocytes in 24-well plates were infected
for 12 h with 1 3 109 pfu/well Ad-GFP or Adgm. Medium was changed to DMEM/FBS with differentiation mixture or DMEM/NBCS 6 1 3 10
27
M ROSIGLITAZONE FOR 48 H. A, Western blotting. Infected pre-adipocytes (minus rosiglitazone) and day 2 adipocytes were scraped and lysed as
described under “Experimental Procedures.” 10 mg of total protein was resolved by SDS-PAGE and immunoblotted with anti-PPARg antibody. B,
aP2 induction by rosiglitazone in pre-adipocytes. Infected pre-adipocytes 6 1 3 1027 M rosiglitazone were lysed and RNA extracted and reverse
transcribed. aP2 gene expression was quantified using real time quantitative PCR as described under “Experimental Procedures.” Data are mean
fold rosiglitazone induction of aP2 6 S.E. C, aP2 induction during differentiation. Infected pre-adipocytes (minus rosiglitazone) and day 2
adipocytes were lysed and RNA extracted and reverse transcribed. aP2 gene expression was quantified using real time quantitative PCR. Data are
mean fold induction of aP2 during differentiation 6 S.E. For experiments B and C, data are from four independent experiments performed in
triplicate, normalized to the endogenous control, glyceraldehyde-3-phosphate dehydrogenase. Ad-GFP data are representative of data from
uninfected cells.
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specifically the time points and particular COX inhibitors stud-
ied. Several groups have demonstrated that certain COX me-
tabolites of AA, particularly the J series of prostaglandins, can
activate PPARg in vitro and could therefore act as endogenous
ligands (21, 26, 27). Our results would suggest that the AA
potentiation of glucose uptake is not mediated via the action of
a COX metabolite on PPARg. However, the involvement of
PPARg in mediating the AA effect on glucose uptake is not
excluded. It is possible that other metabolites, or AA itself,
could act as PPARg activators in this system. It should also be
noted that COX inhibitors themselves have also been demon-
strated to act as ligands at PPARg (47). Ibuprofen was shown to
induce PPARg activity 20-fold at 1024 M but piroxicam had a
negligible effect. The effects of 6-MNA have not been reported.
Lipoxygenase enzymes catalyze the conversion of AA to the
leukotrienes and the hydroxyeicosatetraenoic acid. The enzyme
exists as three isozymes, 5-LOX, 12-LOX, and 15-LOX. We
inhibited the LOX enzyme activity in 3T3-L1 adipocytes for 30
min prior to addition of AA using NDGA, a nonselective LOX
inhibitor. We observed a significant inhibition of the AA poten-
tiation of basal glucose uptake with NDGA. Furthermore, there
was a trend for NDGA to inhibit the AA potentiation of insulin-
stimulated uptake. These results suggest that a LOX metabo-
lite(s) of AA may be involved in its effect on glucose uptake.
Indeed, it has been shown that the 15-LOX metabolites of both
AA and linoleic acid, 15-hydroxyeicosatetraenoic acid and 9-
and 13-hydroxyoctadecadienoic acid, respectively, can function
as micromolar PPARg agonists (29).
The nuclear hormone receptor, PPARg, has recently been
shown to have an important role in the control of insulin
sensitivity (14, 15). Loss of function mutations in human
PPARg result in extreme insulin resistance and diabetes mel-
litus (20). As previously mentioned, several metabolites of AA
have been recognized as potential endogenous ligands for
PPARg. Such metabolites include 15d-PGJ2 (26, 27), D12-PGJ2
(28), and PGD2 (21). It has also been demonstrated that AA
itself can act as a PPARg ligand (22–25). To investigate the role
of PPARg in our system, we inhibited endogenous activity by
transducing fully differentiated adipocytes with a dominant-
negative hPPARg mutant receptor. This mutant form of hP-
PARg has previously been shown to inhibit co-transfected wild-
type receptor action and to inhibit the thiazolidinedione-
induced differentiation of human pre-adipocytes (36). We
demonstrated that the transduced hPPARg mutant receptor
was highly expressed in murine 3T3-L1 pre-adipocytes and
adipocytes and inhibited endogenous wild-type activity. We
then showed that the AA potentiation of basal glucose uptake
was partially, but significantly, inhibited in cells transduced
with the mutant receptor. There was, however, no significant
effect of the mutant receptor on the AA potentiation of insulin-
stimulated glucose uptake. These results suggest that PPARg
activation is at least partly required for the AA effect on glucose
uptake. While the dominant-negative mutant is clearly capable
of specifically inhibiting PPARg function some caveats of this
system should be mentioned. First, although high levels of
infectivity were observed, 3T3-L1 adipocytes are notoriously
difficult to transduce with high efficiency using adenoviruses
and full inhibition of PPARg function in all cells may not have
been achieved. It is also theoretically possible that this domi-
nant-negative mutant might, at high concentrations, occupy
and inhibit transcription through response elements other
than the true native peroxisome proliferator response ele-
ments. Such effects, however, have not actually been
demonstrated.
In summary, we have undertaken the most comprehensive
study to date of the effects of free fatty acids on basal and
insulin-stimulated glucose uptake in an insulin-responsive cell
type. The potentiating effects of even short-term exposure to
AA are at least partially dependent on new protein synthesis
and involve enhanced expression of both GLUT1 and GLUT4 at
the plasma membrane. While activation of PPARg appears to
be necessary, particularly in the absence of insulin, this does
not appear to involve cyclooxygenase metabolites of AA but,
somewhat surprisingly, our results suggest a greater role for
lipoxygenase metabolites in the mediation of this important
metabolic effect.
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